Novel dimethyltyrosine-tetrahydroisoquinoline peptidomimetics with aromatic tetrahydroisoquinoline substitutions show in vitro Kappa and Mu opioid receptor agonism was written by Montgomery, Deanna;Anand, Jessica P.;Griggs, Nicholas W.;Fernandez, Thomas J.;Hartman, Joshua G.;Sanchez-Santiago, Ashley A.;Pogozheva, Irina D.;Traynor, John R.;Mosberg, Henry I.. And the article was included in ACS Chemical Neuroscience in 2019.Recommanded Product: tert-Butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate This article mentions the following:
The dimethyltyrosine-tetrahydroisoquinoline (Dmt-Tiq) scaffold was originally developed in the production of selective delta opioid receptor (DOR) antagonists. Installation of a 7-benzyl pendant on the tetrahydroisoquinoline core of this classic opioid scaffold introduced kappa opioid receptor (KOR) agonism. Further modification of this pendant resulted in retention of KOR agonism and the addition of mu opioid receptor (MOR) partial agonism, a bifunctional profile with potential to be used in the treatment of cocaine addiction. In the experiment, the researchers used many compounds, for example, tert-Butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (cas: 937048-76-5Recommanded Product: tert-Butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate).
tert-Butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (cas: 937048-76-5) belongs to isoquinoline derivatives. Although isoquinoline derivatives can be synthesized by several methods, relatively few direct methods deliver the unsubstituted isoquinoline. It protonates to form salts upon treatment with strong acids, such as HCl. It forms adducts with Lewis acids, such as BF3.Recommanded Product: tert-Butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem